Home

Public Policy

BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Podcast: BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

BIO's 2012 Legislative Priorities - Part II

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations.

2011: A Pivotal Year for Biotechnology

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world.

BIO's 2012 Legislative Priorities

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations. In this two part series, Del Monte discusses the outlook for 2012 and legislative priorities.

New Orleans Biotech Center Drives Job Growth and Diversifies Economy

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

Capital Formation Spurs Job Growth

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

Can a 21st Century FDA Accelerate Biotech Innovation to Cure Disease and Save Lives?

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

How States Can Foster and Expand Biotech Industry Development

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Becoming a Part of the Biotech Industry

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Capital Conundrum

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

What Do Voters Think About the Biotechnology Industry?

What is your opinion of biotechnology companies – very favorable, somewhat favorable, somewhat unfavorable, or very unfavorable?

BIO Grassroots Handbook

A strong Network will bolster public awareness of the industry and encourage more investment dollars.

Unleashing the Promise of Biotechnology

Society has tapped just a small fraction of the many potential uses and benefits of biotechnology.

Jim Greenwood's Address at the 2011 BIO International Convention

Mankind's need to cure disease, combat hunger and discover new forms of energy has never been more urgent.

Letters, Testimony & Comments

Cell and Gene Therapy: BIO Comments on Preclinical Assessment of Investigational Cellular and Gene Therapy Products
February 27 2013
    Dear Sir/Madam:    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration...
Electronic Submissions: BIO Comments on Providing Submissions in Electronic Format
February 19 2013
    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the...
SMU: BIO Statement on Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need
February 4 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to provide...
BIO Principles on Patient Safety in the Substitution of Biologic Products
January 24 2013
Biologics are complex medicines manufactured from living organisms. Unlike traditional “small molecule” drugs, biologics are...
Statement in Support Of North Dakota S.B. 2190
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
More Letters, Testimony & Comments →

Press Releases

BIO Strongly Opposes RFS Waiver Requests in Comments to EPA
October 9 2012
Any waiver of the RFS would have little to no effect on corn prices, but would certainly harm biofuel producers and...
BIO Praises Introduction of the High Technology Small Business Research Incentives Act
September 25 2012
Washington, D.C. (September 25, 2012) – The Biotechnology Industry Organization (BIO) applauds Sens. Robert...
BIO Opposes A Northern California County's New Drug Disposal Law
July 27 2012
Washington, D.C. (July 27, 2012) – Biotechnology Industry Organization (BIO) Vice President of Alliance ...
Bioscience Industry Adds Jobs Over the Last Decade, Despite Economic Setbacks for the Nation
June 19 2012
Fifth biennial report by Battelle outlines 6.4% job growth in sector from 2001 to 2010,while overall economy recorded...
New Jersey Governor Chris Christie Presented 2012 BIO Governor of the Year Award
June 14 2012
WASHINGTON, DC (June 12, 2012) – The Biotechnology Industry Organization (BIO) announced today that New Jersey...
More Press Releases →